Search Results - "Bota, D A"

TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth by Di, K, Linskey, M E, Bota, D A

“…TRIM11 (tripartite motif-containing protein 11), an E3 ubiquitin ligase, is known to be involved in the development of the central nervous system. However,…”
Get full text

Impairment of Lon-Induced Protection Against the Accumulation of Oxidized Proteins in Senescent Wi-38 Fibroblasts by Ngo, Jenny K., Pomatto, Laura C. D., Bota, Daniela A., Koop, Alison L., Davies, Kelvin J. A.

“…Oxidative damage to mitochondrial proteins is thought to contribute to the aging process, but the Lon protease normally degrades such proteins. In…”
Get full text

P063 Interleukin-8 mucosal transcript as predictor of response to Vedolizumab treatment in Ulcerative Colitis: preliminary results from a prospective study by Bota, A D, Mușa, A M, Dinu, M C, Săftoiu, A, Mușa, M, Coman, S, Dobre, M, Milanesi, E, Țieranu, C G

“…Abstract Background Vedolizumab (VDZ) is a safe, well tolerated and efficient biologic agent used for the treatment of inflammatory bowel disease (IBD), as…”
Get full text

RH-01 THE SIGNIFICANCE OF ACUTE INPATIENT REHABILITATION FOR GLIOMA PATIENTS: IMPROVING THE PHYSICAL FUNCTION, QUALITY OF LIFE AND SURVIVAL by Beverly Fu, D., Bota, D. A.

“…OBJECTIVE: To assess the effects of inpatient acute rehabilitation on overall function, quality of life and overall survival for glioma patients. DESIGN: A…”
Get full text

Novel use of MR spectroscopy in detecting CSF lactate for diagnosis of neoplastic meningitis by Weston, C. L., Zalatimo, O., Sheehan, J., Harbaugh, R., Bota, D. A., Shedden, A., Glantz, M. J.

“…Abstract only…”
Get full text

Retrospective analysis of temozolomide (TMZ) plus BCNU wafers and TMZ alone in the primary treatment of glioblastoma multiforme by Bota, D. A., Taylor, S. A.

“…Abstract only 11519 Background: GBM is the most common and aggressive primary brain tumor with a median survival around 1 year. Two agents have shown promise…”
Get full text

Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma by Bota, D. A., Eroglu, Z., Reardon, D. A., Fu, B. D., Norfleet, J., Desjardins, A., Linskey, M. E., Peters, K., Friedman, H. S., Vredenburgh, J. J.

“…Abstract only…”
Get full text

Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism by Davies, Kelvin J. A, Bota, Daniela A

“…Mitochondrial aconitase is sensitive to oxidative inactivation and can aggregate and accumulate in many age-related disorders. Here we report that Lon…”
Get full text

Downregulation of the human Lon protease impairs mitochondrial structure and function and causes cell death by Bota, Daniela A., Ngo, Jenny K., Davies, Kelvin J.A.

“…Lon now emerges as a major regulator of multiple mitochondrial functions in human beings. Lon catalyzes the degradation of oxidatively modified matrix…”
Get full text

Modulation of Lon protease activity and aconitase turnover during aging and oxidative stress by Bota, Daniela A, Van Remmen, Holly, Davies, Kelvin J.A

“…We compared Lon protease expression in murine skeletal muscle of young and old, wild-type and Sod2 −/+ heterozygous mice, and studied Lon involvement in the…”
Get full text

Tinzaparin prophylaxis in brain tumor patients by Bohlin, C. W., Reardon, D. A., Desjardins, A., Quinn, J. A., Rich, J. N., Bota, D. A., Goli, K., Friedman, H. S., Vredenburgh, J. J.

“…Abstract only 12506 Background: Thromboembolic disease is the second leading cause of death in brain tumor patients. Various studies have documented a 20–40%…”
Get full text

Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma by Bota, D. A., Desjardins, A., Quinn, J. A., Rich, J. N., Vredenburgh, J. J., Sathornsumetee, S., Goli, K., Salvado, A., Friedman, H. S., Reardon, D. A.

“…Abstract only 2053 Background: We evaluated the combination of imatinib mesylate and hydroxyurea in recurrent/progressive low-grade gliomas (LGG) following the…”
Get full text

Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas by Goli, K. J., Desjardins, A., Herndon, J. E., Rich, J. N., Reardon, D. A., Quinn, J. A., Sathornsumetee, S., Bota, D. A., Friedman, H. S., Vredenburgh, J. J.

“…Abstract only 2003 Background: Recurrent malignant gliomas have low response rates to current treatments. Malignant gliomas have high concentrations of VEGF…”
Get full text

ED-38 AN UPDATED ANALYSIS OF PATIENT REGISTRY DATA ON NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA by Wong, E. T., Engelhard, H. H., Tran, D. D., Kew, Y., Mrugala, M. M., Cavaliere, R., Villano, J. L., Bota, D. A., Rudnick, J., Sumrall, A. L., Zhu, J. J.

Get full text

Pilot study of dronabinol for adult patients with primary malignant gliomas by Vredenburgh, J. J., Bohlin, C. H., Reardon, D. A., Desjardins, A., Quinn, J. A., Rich, J. N., Bota, D. A., Goli, K. J., Friedman, H. S., Allen, D. H.

“…Abstract only 19607 Background: Chemotherapy-induced nausea and vomiting (CINV) are common adverse effects from chemotherapy. While most treatments…”
Get full text

Neuro-cognitive by O'Neil, S. H., Azoff, J., Buranahirun, C., Dhall, G., Panigrahy, A., Borchert, M., Khatua, S., Ji, L., Sposto, R., Finlay, J., Gong, X., Schwartz, P., Linskey, M., Bota, D. A., Wefel, J. S., Patwardhan, S. Y., Strange, C., Emily, F., Celine, A., Penelope, K., Anne-Sophie, C., Rolando, D. M., Michael, P., Correa, D. D., Shi, W., Abrey, L., DeAngelis, L., Thaler, H., Habets, E. J., Walchenbach, R., Kloet, A., Zwinkels, H., Klein, M., Vecht, C. J., Taphoorn, M. J., Ambachtsheer, N., van Nieuwenhuizen, D., Heimans, J. J., Reijneveld, J. C., Peerdeman, S. M., Lagemaat, C., Peters, K. B., Reardon, D. A., Vredenburgh, J. J., Desjardins, A., Friedman, H. S., Driever, P. H., Koustenis, E., Henze, G., De Sonneville, L., Rueckriegel, S. M., Mok, K., Klein, D., Del Maestro, R., Petrecca, K., Olivier, A., Schanker, B. D., Curry, W. T., Edelstein, K., Spiegler, B. J., Fung, S., Panzarella, T., Hodgson, D. C., Mabbott, D. J., Laperriere, N., Tabori, U., Bouffet, E., Mason, W. P.

Get full text

Medical and Neuro-Oncology by Barker, C. A., Chang, M., Lassman, A. B., Beal, K., Chan, T. A., Hunter, K., Grisdale, K., Ritterhouse, M., Moustakas, A., Iwamoto, F. M., Kreisl, T. N., Sul, J., Kim, L., Butman, J., Albert, P., Fine, H. A., Chamberlain, M. C., Alexandru, D., Glantz, M. J., Bota, D. A., Takahashi, K., Ikeda, N., Kajimoto, Y., Miyatake, S., Kuroiwa, T., Iwamoto, F., Lamborn, K., Kuhn, J., Wen, P., Yung, W. K. A., Gilbert, M., Chang, S., Lieberman, F., Prados, M., Fine, H., Lu-Emerson, C., Norden, A. D., Drappatz, J., Quant, E. C., Ciampa, A. S., Doherty, L. M., LaFrankie, D. C., Wen, P. Y., Sherman, J. H., Moldovan, K., Yeoh, H. K., Starke, B. M., Pouratian, N., Shaffrey, M. E., Schiff, D., O'Connor, P. C., Kroon, H.-A., Recht, L., Montano, N., Cenci, T., Martini, M., D'Alessandris, Q. G., Banna, G. L., Maira, G., De Maria, R., Larocca, L. M., Pallini, R., Kim, C. H., Yang, M. S., Cheong, J. H., Kim, J. M., Shonka, N., Alfred Yung, W. K., Piao, Y., Liu, J., Bekele, N., Chen, A., Heymach, J., de Groot, J., Gilbert, M. R., Wang, M., Aldape, K., Sorensen, A. G., Mikkelsen, T., Bokstein, F., Woo, S. Y., Chmura, S. J., Choucair, A. K., Mehta, M., Perez Segura, P., Gil, M., Balana, C., Chacon, I., Munoz, J., Martin, M., Flowers, A., Salner, A., Gaziel, T. B., Soerensen, M., Hasselbalch, B., Poulsen, H. S., Lassen, U., Peyre, M., Cartalat-Carel, S., Meyronet, D.

Get full text

Quality of Life by Lucas, M. R., Armstrong, T. S., Acquaye, A., Balachandran, D., Mahajan, A., Kang, D.-H., Vera-Bolanos, E., Gilbert, M. R., Lovely, M. P., Page, M., Mogensen, K., Arzbaecher, J., Amidei, C., Lupica, K., Maher, M. E., Sherwood, P., Kagan, S., Sizoo, E. M., Pasman, H. R. W., Reijneveld, J. C., Heimans, J. J., Deliens, L., Taphoorn, M. J., Sheth, R., Bagan, B. T., Baig, M. N., Karas, C., Jacobs, D. I., Grimm, S. A., Rademaker, A., Rice, L., Chandler, J. P., Muro, K., Marymount, M., Helenowski, I. B., Wagner, L. I., Bennett, C. L., Raizer, J. J., Evans, A., Dhall, G., Finlay, J., Wong, K., McComb, G., Soffietti, R., Mueller, R. P., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B., Fariselli, L., Tridello, G., Kocher, M., Bottomley, A., Pendleton, C., Adams, H., Jallo, G. I., Carson, B. S., Ahn, E., Quinones-Hinojosa, A., Acquaye, A. A., Bekele, B. N., Chandler, J., Nestor, V., Fink, K., Nashed, M., Linskey, M., Bota, D. A., Hoeben, W., Hilverda, K., Postma, T. J., Buter, J., Lenting, J., Collette, E. H., Klein, M., van Nieuwenhuizen, D., Bosscher, L., Szymanska, E., Peerdeman, S. M., Erdmann, T., Lawrence Recht, S. N., Armstrong, T., Gning, I., Cleeland, C., Mendoza, T. R., Jouniaux-Delbez, N., Delattre, J. Y., du Montcel, S. T., Butowski, N., Parvataneni, R., Nicole, A., Lamborn, K., Polley, M., Clarke, J., Chang, S., Prados, M., Liepa, A., Shi, P., Thornton, D., Kahlenberg, C. A., Fadul, C. E.

Get full text

Adherence to Prophylactic Anticonvulsant Guidelines for Newly Diagnosed Brain Tumor Patients: A Quality Improvement Study by Fu, Dan Beverly, Kong, Xiao-Tang, Veenema, Tener Goodwin, Bota, Daniela A, Koirala, Binu

“…Clinical guidelines suggest that prophylactic antiepileptic drugs (AEDs) should be given to newly diagnosed seizure-naive brain tumor patients for up to 1 week…”
Get full text

The Dynamics of Insight in the Prodrome of Schizophrenia by Bota, Robert G., Munro, J. Stuart, Ricci, Walter F., Bota, Daniela A.

“…Schizophrenia is characterized by diminished insight, which fluctuates with disease progression. Insight deterioration in the prodrome of schizophrenia is…”
Get full text